Wedbush Brokers Lower Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Wedbush decreased their Q2 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Monday, July 14th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($1.12) per share for the quarter, down from their previous estimate of ($1.08). Wedbush currently has a “Neutral” rating and a $34.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.66) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS, FY2028 earnings at $0.31 EPS and FY2029 earnings at $1.87 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business’s quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the firm earned ($2.03) earnings per share.

A number of other research analysts have also recently weighed in on RARE. Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price target for the company. JPMorgan Chase & Co. increased their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Guggenheim reissued a “buy” rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, July 10th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $83.64.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $27.31 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $26.85 and a 1-year high of $60.37. The business’s 50 day moving average is $36.00 and its two-hundred day moving average is $38.46. The stock has a market capitalization of $2.58 billion, a P/E ratio of -4.64 and a beta of 0.26.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 3,167 shares of company stock valued at $118,824 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 669 shares during the period. GAMMA Investing LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $35,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $57,000. Finally, Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $59,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.